Great expectations in stereochemistry: Focus on antidepressants

CNS Spectrums

Volumn 7, Issue 4 SUPPL. 1, 2002, Pages 28-33

  DeVane, C Lindsay ^a   Boulton, David W ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; METHADONE; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE; VILOXAZINE;

CHIRALITY; CONFERENCE PAPER; ENANTIOMER; OUTCOMES RESEARCH; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RACEMIC MIXTURE; STEREOCHEMISTRY;

EID: 0036083854     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900028571     Document Type: Conference Paper

References (37)

1. Development and application of a chiral high pressure liquid chromatography assay for pharmacokinetic studies of methadone
2. Pharmacokinetics and pharmacodynamics of methadone enantiomers in normal female volunteers following a single oral dose of racemate
3. Effects of tranylcypromine enantiomers on monoamine uptake and release and imipramine binding
4. Direct separation of tranylcypromine enantiomers and their profile in an atypical depressive patient
5. Enantiospecific high-performance liquid chromatographic assay with fluorescence detection for the monoamine oxidase inhibitor tranylcypromine and its applicability in pharmacokinetic studies
6. Trimipramine: Pharmacological reevaluation and comparison with clozapine
7. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP 2D6-, CYP 2C19- and CYP 3A4/5-phenotyped patients
8. Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion
9. Antidepressant profile of bupropion and three metabolites in mice
10. Enantiomeric determination of the phenylmorpholinol metabolite of bupropion in human plasma using coupled achiral-chiral liquid chromatography
11. Venlafaxine oxidation in vitro is catalysed by CYP 2D6
12. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants
13. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite
14. The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine
15. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: A case report
16. Venlafaxine serum levels and CYP 2D6 genotype
17. Stereoselective and species-dependent kinetics of reboxetine in mouse and rat
18. Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics
19. Comparison of the disposition and of the metabolic pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man
20. Cytochrome P450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes
21. Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding
22. Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors
23. Drug concentrations in mouse brain at pharmacologically active doses of fluoxetine enantiomers
24. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
25. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450
26. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes
27. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine
28. Fluoxetine isomer may hold advantages over Prozac
29. S-fluoxetine in the prophylaxis of migraine: A phase II double-blind randomized placebo-controlled study
30. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes
31. The S-enantiomer of citalopram (Lu 26-054): Cytochromes P450 mediating metabolism and cytochrome inhibitory effects
32. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography
33. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans
34. Stereoselective HPLC-assay for citalopram and its metabolites
35. Plasma levels of citalopram enantiomers and metabolites in elderly patients
36. The FDA perspective on the development of stereoisomers
37. Fixed dose study of escitalopram in the treatment of depression